Home › Zenth Health Sciences › Therapeutics

Advancing Precision Medicine

From molecular target discovery to clinical translation, Zenth Therapeutics is engineering next-generation treatments for unmet medical needs worldwide.

Current Pipeline

Clinical Development Stages

Our proprietary drug discovery engines are accelerating novel compounds through rigorous clinical validation.

ZTH-402 Phase III
Metastatic Pancreatic Adenocarcinoma
First-in-class KRAS G12C/HRD dual inhibitor with immune checkpoint modulation
Primary Endpoint: PFS Q3 2026 Data Readout
ZTH-819 Phase II
Early-Onset Alzheimer's Disease
Tau protein aggregation disruptor with enhanced BBB penetration vectors
\n
Primary Endpoint: CDR-SB Enrollment: 85% Complete
ZTH-114 Phase I
Refractory Systemic Sclerosis
Selective JAK3/TEC kinase inhibitor with fibroblast quiescence profile
Primary Endpoint: MTD/Safty First-in-Human: Active
ZTH-550 Pre-Market
Biliary Tract Cancer
Antibody-drug conjugate targeting FGFR4 with topoisomerase I payload
Primary Endpoint: ORR BLA Submission: Q1 2025
Therapeutic Focus

Target Indications

We prioritize disease areas with high clinical burden and limited existing treatment options.

🧬
Oncology
Solid tumors, hematologic malignancies, and resistance pathway modulation
🧠
Neurology
Neurodegenerative disorders, cognitive preservation, and blood-brain barrier targeting
❤️
Cardiovascular
Heart failure, atherosclerosis modulation, and metabolic-cardiac cross-talk therapies
🔬
Rare Diseases
Orphan indications, genetic disorders, and population-specific molecular targets
🛡️
Immunology
Autoimmune modulation, cytokine pathway inhibition, and microbiome-immune interfaces
Technology

Discovery Platforms

Cross-divisional innovation fuels our proprietary therapeutic development engines.

Zenth AI Drug Design
Generative molecular modeling, predictive ADMET profiling, and multi-objective optimization algorithms trained on 2.4B compound-property datasets.
Deep Learning Protein Folding De Novo Design
CRISPR-Prime Editing Suite
High-fidelity genome editing for functional validation, knockout/knockin disease models, and next-generation gene therapy candidates.
Base Editing AAV Vectors Off-Target Screening
Organ-on-Chip Physiology
Microphysiological systems mimicking human tissue responses for toxicity screening, efficacy modeling, and personalized medicine trials.
Microfluidics High-Throughput Human Cells
Clinical Operations

Trial Execution & Data

Rigorous, patient-centric trial design across global research networks.

42
Active Trials
186
Global Sites
14
Phase III Programs
98.2%
Protocol Adherence
Study ID Compound Indication Phase Regions Status
NCT-05882190 ZTH-402 Pancreatic Cancer III NA, EU, APAC Recruiting
NCT-06110442 ZTH-819 Alzheimer's Disease II NA, EU Active
NCT-05993881 ZTH-114 Systemic Sclerosis I NA Active
NCT-05771209 ZTH-550 Biliary Tract Cancer III Global Completed

Scientific Partnerships & Trials

Collaborate on drug development, join clinical research networks, or explore licensing opportunities with Zenth Therapeutics.

Partner With Us → Find Clinical Trials